Olr1350 inhibitors are a specific class of chemical compounds designed to target and inhibit the Olr1350 receptor, an olfactory receptor that belongs to the extensive G protein-coupled receptor (GPCR) superfamily. These receptors are integral to the olfactory system, where they play a crucial role in detecting and processing a wide range of odorant molecules, leading to the perception of smells. Olr1350 inhibitors function by binding to the receptor's active site, where natural odorants typically bind, or by interacting with allosteric sites that modulate the receptor's activity. This binding effectively blocks the receptor from undergoing the conformational changes necessary for activating downstream signaling pathways, thus preventing the transmission of olfactory signals. The development and design of these inhibitors are often informed by detailed structural studies of the Olr1350 receptor, utilizing advanced techniques such as X-ray crystallography, molecular modeling, and cryo-electron microscopy. These techniques provide crucial insights into the receptor's binding pockets and other structural features, enabling the creation of inhibitors that are both highly specific and effective in modulating the receptor's activity.
Chemically, Olr1350 inhibitors exhibit a wide range of molecular structures, reflecting the diverse approaches taken in their synthesis. These compounds may range from small, lipophilic molecules capable of easily penetrating cellular membranes to reach their target receptors, to larger, more complex structures that require sophisticated synthetic strategies to optimize their binding affinity and specificity. The synthesis of Olr1350 inhibitors typically involves multiple steps of organic chemistry, including the construction of molecular frameworks and the incorporation of functional groups that enhance the compound's interaction with the receptor. Once synthesized, these inhibitors undergo rigorous characterization using a variety of analytical techniques, such as nuclear magnetic resonance (NMR) spectroscopy, mass spectrometry, and high-performance liquid chromatography (HPLC). These methods ensure that the inhibitors possess the desired structural integrity, purity, and inhibitory potency. The study of Olr1350 inhibitors is important for advancing our understanding of the specific mechanisms by which this olfactory receptor functions and how its activity can be modulated by small molecules. Additionally, this research contributes to the broader field of GPCR modulation, offering valuable insights into the molecular processes underlying sensory perception, particularly in the context of olfaction. By deepening our knowledge of how olfactory receptors function and how they can be selectively targeted, scientists can explore new avenues in the study of sensory systems and the complex biochemical pathways that govern them.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
EGFR tyrosine kinase inhibitor, may disrupt cell signaling involved in tumor growth and survival. | ||||||
Afatinib | 439081-18-2 | sc-364398 sc-364398A | 5 mg 10 mg | $114.00 $198.00 | 13 | |
Irreversible EGFR inhibitor, designed to bind covalently to cancer cell receptors, blocking proliferation. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
RAF kinase inhibitor, interrupts cell signaling in cancer cells, potentially inhibiting tumor growth. | ||||||
Regorafenib | 755037-03-7 | sc-477163 sc-477163A | 25 mg 50 mg | $320.00 $430.00 | 3 | |
Multi-kinase inhibitor, targeting angiogenic, stromal, and oncogenic kinases. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
MEK1/2 inhibitor, disrupts the MAPK/ERK pathway, which may affect cell division and proliferation. | ||||||
Dabrafenib | 1195765-45-7 | sc-364477 sc-364477A sc-364477B sc-364477C sc-364477D | 5 mg 25 mg 50 mg 100 mg 10 g | $141.00 $260.00 $278.00 $411.00 $12485.00 | 6 | |
BRAF inhibitor, designed for melanomas with specific genetic mutations in the BRAF gene. | ||||||
Lenvatinib | 417716-92-8 | sc-488530 sc-488530A sc-488530B | 5 mg 25 mg 100 mg | $182.00 $661.00 $1690.00 | 3 | |
Multi-target inhibitor, affects VEGFR, FGFR, PDGFR, RET, and KIT signaling. | ||||||
XL-184 free base | 849217-68-1 | sc-364657 sc-364657A | 5 mg 10 mg | $94.00 $208.00 | 1 | |
Inhibitor of MET, VEGFR, and AXL, potentially affecting cell growth, angiogenesis, and metastasis. | ||||||
Pazopanib | 444731-52-6 | sc-396318 sc-396318A | 25 mg 50 mg | $130.00 $182.00 | 2 | |
Multi-targeted kinase inhibitor, including VEGFR, PDGFR, and KIT, may affect tumor angiogenesis. | ||||||
CH5424802 | 1256580-46-7 | sc-364461 sc-364461A | 5 mg 50 mg | $191.00 $902.00 | ||
It is an ALK inhibitor. | ||||||